Literature DB >> 10403094

Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum beta-lactamases.

D Shen1, D J Biedenbach, P L Winokur, M A Pfaller, R N Jones.   

Abstract

Twenty-three multi-resistant strains of Escherichia coli were isolated at a single hospital in Beijing, China between January 1997 and May 1998. All isolates produced extended spectrum beta-lactamases (ESBLs) as detected by the double disk synergy test and the Etest ESBL strip (AB BIODISK, Solna Sweden). Additional antimicrobial susceptibility testing showed that most isolates were resistant to gentamicin, tobramycin, tetracycline, trimethoprim/sulfamethoxazole, ciprofloxacin, and cefepime. All isolates remained susceptible to imipenem with MICs of < or = 0.5 microgram/ml. The isolates each produced several beta-lactamases (range 1-4 enzymes/strain) with pI values ranging from 5.2-8.4. Molecular epidemiologic typing revealed four ribotypes and eight pulsed field gel electrophoresis (PFGE) patterns with subgroups among the 23 isolates. Clusters of isolates with the same DNA type were observed as follows (ribotype/PFGE): Wards A (242-5/2, and 242-5/3a), B (242-5/4), and C (880-1/1a). Moreover, similar molecular types were observed in patients from two or more different wards. Further use of isoelectric focusing results and co-resistance patterns produced evidence of potential nosocomial dissemination of strains in only two instances (two identical strains on one ward and two identical strains on different wards). There were also strong similarities in beta-lactamase pIs and co-resistances among many of the strains throughout this medical center. These data document the wide genetic diversity among E. coli producing ESBLs, and a potential for nosocomial spread of these highly resistant organisms requiring increasingly more sophisticated molecular-based techniques and local interventions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403094     DOI: 10.1016/s0732-8893(99)00018-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China.

Authors:  Aroonwadee Chanawong; Fatima Hannachi M'Zali; John Heritage; Jian-Hui Xiong; Peter Michael Hawkey
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China.

Authors:  Hui Wang; Swathi Kelkar; Weiyuan Wu; Minjun Chen; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

4.  Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam.

Authors:  Van Cao; Thierry Lambert; Duong Quynh Nhu; Huynh Kim Loan; Nguyen Kim Hoang; Guillaume Arlet; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Molecular epidemiology of the integron-located VEB-1 extended-spectrum beta-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand.

Authors:  D Girlich; L Poirel; A Leelaporn; A Karim; C Tribuddharat; M Fennewald; P Nordmann
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

6.  Characterization of multidrug-resistant Escherichia coli isolates associated with nosocomial infections in dogs.

Authors:  Susan Sanchez; M A McCrackin Stevenson; Charlene R Hudson; Marie Maier; Tameka Buffington; Quyen Dam; John J Maurer
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.